Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
DXS International plc : Half-year Report | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
By: Nasdaq / GlobeNewswire - 31 Jan 2018 | Back to overview list |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DXS INTERNATIONAL PLC HALF YEAR REPORT DXS International plc ("DXS" or "the Company"), the NEX Growth Market quoted healthcare information and clinical decision support systems provider today announces its half year report for the 6 month period ending 31 October 2017. As DXS has previously indicated Government budget cuts and reorganisations within the NHS have severely affected our plans for organic growth during the past year. With the cuts in CCG budgets adversely affecting both sales and retention of existing clients, turnover fell by 7% in the second half of the last financial year and a further 2.5% in the first half of the current financial year. The decline has now been arrested and we have been able to source additional loans to be able to continue our investment in our new products (outlined below). While the outcome for the six months to October 2017 is disappointing, the Board believes that the Company is now on the turn back to growth. The NHS have informed us that the new GPSoC 3 tender will happen this year and that they intend addressing the shortcomings of GPSoC 2 during the past two years which have made business difficult for many NHS suppliers. Management are confident that the Company is poised to achieve significant growth over the next three years. The basis for the positive outlook is founded on the following premises:
DXS has spent the past three years innovating and developing cutting edge solutions that will contribute to helping manage patients with long term conditions. These products are generating impressive feedback from the clinicians who have seen them.
A pilot of all of the foregoing has commenced at Warrington, focusing on one of the most significant and complex major long term conditions - hypertension. There are three additional pilots addressing Diabetes, Pregnancy and Arthritis and the initial response is very positive. The roll out of these pilots is a major focus for the Company. While DXS continues to invest in R&D, management has planned an aggressive sales and marketing campaign to achieve significant revenue growth over the next three years. The Board is focused on continuing to improve communication with shareholders and has introduced a programme of newsletters. If you wish to be added to the circulation list of recipients please contact our office on +441252719800 or send an email to info@dxs-systems.co.uk. David Immelman INTERIM RESULTS TO 31 OCTOBER 2017 CONSOLIDATED PROFIT AND LOSS ACCOUNT for the six month period ended 31 October 2017
. CONSOLIDATED BALANCE SHEET as at 31 October 2017
The above figures have not been reviewed by the company's auditors LDP Luckmans. The Directors of DXS International plc accept responsibility for this announcement Contacts:
Notes to Editors About DXS: DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |